Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer. Via Krishan Maggon 
Scoop.it!
VentiRx is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. Via Krishan Maggon
|
Scoop.it!
Highlights Via Krishan Maggon
Krishan Maggon 's curator insight,
January 30, 2015 8:49 AM
Molecular Immunology
Available online 13 January 2015 In Press, Corrected Proof — Note to users Review Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic ☆Connie P.M. Duonga, b, c, Carmen S.M. Yonga, b, Michael H. Kershawa, b, c, d, Clare Y. Slaneya, b, 1, , ,Phillip K. Darcya, b, c, d, 1, , doi:10.1016/j.molimm.2014.12.009
Scoop.it!
From
lbio
TIL Technology In the early stages of cancer, special immune cells known as tumor infiltrating lymphocytes (TILs) migrate to the tumor and launch an attack. However, this effect is usually short-lived because cancer adapts to evade immune detection and suppress immune response. Lion’s TIL technology is designed to overcome the immunosuppressive effects of cancer, while leveraging and enhancing the power of TILs to treat, and potentially cure, all solid tumors. Our TIL technology has demonstrated robust efficacy in Phase 2 clinical trials, indicating objective response rates of 49% in Stage 4 metastatic melanoma. Based on an adoptive cell therapy regimen developed by Steven A. Rosenberg, MD, chief of surgery at National Cancer Institute (NCI), it is currently in use as a physician-sponsored investigational treatment for Stage IV metastatic melanoma at NCI, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute. Via Krishan Maggon
Gilbert C FAURE's insight:
TIL back on stage? they are not in memories of most students
Krishan Maggon 's curator insight,
July 23, 2014 10:13 PM
Lion Biotech TIL is in Phase II trials in advanced metastatic melanoma and in Phase I trials in combination with BRAF inhibitor Zelboraf (vemurafenib, Roche) and in another Phase I with Yervoy (Ipilimumab, BMS). all trials are with NCI. |
Review
Cancer Gene Therapy advance online publication 27 February 2015; doi: 10.1038/cgt.2014.81
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
X Wang1,2 and I Rivière1,2,3
1Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA2Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA3Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Correspondence: Dr I Rivière, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 182, New York, NY 10065, USA. E-mail: rivierei@mskcc.org
Received 21 October 2014; Accepted 10 December 2014
Advance online publication 27 February 2015